Evaluating AMH levels in adolescents with PCOS: A retrospective cohort study
Presenter Status
Fellow
Abstract Type
Clinical Research
Primary Mentor or Principal Investigator
Tazim Dowlut-McElroy
Presentation Type
Poster
Start Date
21-5-2026 11:00 AM
End Date
21-5-226 12:00 PM
Abstract Text
Background: Anti-Müllerian Hormone (AMH) has been used as a marker of Polycystic Ovarian Syndrome (PCOS) in adults since the 2010s with formal recognition in 2023 (1). However, the diagnostic criteria for PCOS in the pediatric population is limited to oligomenorrhea and hyperandrogenism. This study aimed to evaluate whether AMH could serve as an additional diagnostic criterion for pediatric and adolescent patients with PCOS.
Methods: A retrospective chart review was conducted on 23 patients aged 13–17 years old who were diagnosed with PCOS at Children’s Mercy Kansas City Hospital (figure 1). Demographic information analyzed included patient race, ethnicity, and primary language. Data collected included age, body mass index (BMI), age of menarche, cycle duration, follicle-stimulating hormone (FSH), luteinizing hormone (LH), thyroid-stimulating hormone (TSH), estradiol, progesterone, prolactin, AMH levels, lipid profiles, and comorbid conditions such as anxiety, depression, hyperlipidemia, and elevated blood pressure. AMH was the primary outcome of interest. Descriptive statistics were generated for all variables. Pearson correlation coefficients were calculated to evaluate associations between AMH levels and other datapoints of interest, with statistical significance set at p< 0.05. Analyses were performed using SPSS software.
Results: The mean AMH level was 7.59 ng/mL. Although this is within the reported normal range of 6.2–7.8 ng/mL, the standard deviation was 4.74 ng/mL with an interquartile range of 8.4 ng/mL and values ranging from 0.95 ng/mL to 18.00 ng/mL. The 0.95 ng/mL value appears to be an outlier, as the most frequent AMH level observed was 12.00 ng/mL, well above the accepted cutoff. Additionally, there was a significant negative correlation (Pearson correlation coefficient = –0.467, p< 0.05) between AMH level and BMI which is consistent with previously reported literature (2).
Conclusions: AMH levels appear to be a promising diagnostic marker for pediatric and adolescent PCOS. Although the average AMH level was within the expected range, the distribution was negatively skewed, with the most frequent level being 12.00 ng/mL (Figure 2). Age-based AMH thresholds proposed in recent adult studies (≥6.93 ng/mL for 20–27 years, ≥5.06 ng/mL for 28–30 years, ≥4.19 ng/mL for 31–39 years) are lower than the current cutoff, suggesting the need to reconsider pediatric thresholds (3). Larger studies are warranted to validate these findings and further assess the role of AMH in diagnosing PCOS in the pediatric and adolescent population
Evaluating AMH levels in adolescents with PCOS: A retrospective cohort study
Background: Anti-Müllerian Hormone (AMH) has been used as a marker of Polycystic Ovarian Syndrome (PCOS) in adults since the 2010s with formal recognition in 2023 (1). However, the diagnostic criteria for PCOS in the pediatric population is limited to oligomenorrhea and hyperandrogenism. This study aimed to evaluate whether AMH could serve as an additional diagnostic criterion for pediatric and adolescent patients with PCOS.
Methods: A retrospective chart review was conducted on 23 patients aged 13–17 years old who were diagnosed with PCOS at Children’s Mercy Kansas City Hospital (figure 1). Demographic information analyzed included patient race, ethnicity, and primary language. Data collected included age, body mass index (BMI), age of menarche, cycle duration, follicle-stimulating hormone (FSH), luteinizing hormone (LH), thyroid-stimulating hormone (TSH), estradiol, progesterone, prolactin, AMH levels, lipid profiles, and comorbid conditions such as anxiety, depression, hyperlipidemia, and elevated blood pressure. AMH was the primary outcome of interest. Descriptive statistics were generated for all variables. Pearson correlation coefficients were calculated to evaluate associations between AMH levels and other datapoints of interest, with statistical significance set at p< 0.05. Analyses were performed using SPSS software.
Results: The mean AMH level was 7.59 ng/mL. Although this is within the reported normal range of 6.2–7.8 ng/mL, the standard deviation was 4.74 ng/mL with an interquartile range of 8.4 ng/mL and values ranging from 0.95 ng/mL to 18.00 ng/mL. The 0.95 ng/mL value appears to be an outlier, as the most frequent AMH level observed was 12.00 ng/mL, well above the accepted cutoff. Additionally, there was a significant negative correlation (Pearson correlation coefficient = –0.467, p< 0.05) between AMH level and BMI which is consistent with previously reported literature (2).
Conclusions: AMH levels appear to be a promising diagnostic marker for pediatric and adolescent PCOS. Although the average AMH level was within the expected range, the distribution was negatively skewed, with the most frequent level being 12.00 ng/mL (Figure 2). Age-based AMH thresholds proposed in recent adult studies (≥6.93 ng/mL for 20–27 years, ≥5.06 ng/mL for 28–30 years, ≥4.19 ng/mL for 31–39 years) are lower than the current cutoff, suggesting the need to reconsider pediatric thresholds (3). Larger studies are warranted to validate these findings and further assess the role of AMH in diagnosing PCOS in the pediatric and adolescent population
Comments
Full text not provided by primary author
Poster Board Number: 21